Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population

W. R. Grubb, H. J. Neboori, A. D. Diaz, H. Li, D. Kwon, Joseph Panoff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Little is known about the association between race/ethnicity and survival in pediatric Hodgkin lymphoma (HL) patients. In a state-wide pediatric cohort diagnosed with HL, we assessed demographic, disease, and treatment characteristics associated with overall survival (OS). We then attempted to validate these findings and assess disease-specific survival (DSS) in a national Surveillance, Epidemiology, and End Results (SEER) cohort. Procedure: HL patients of 0.1-21 years diagnosed from 1981 to 2010 were evaluated using the Florida Cancer Data System (FCDS). Kaplan-Meier curves estimated OS from 5 to 25 years based on race/ethnicity, treatment, decade of diagnosis, and sex. Multivariate Cox proportional hazard regressions tested independent factors associated with differences in OS. These methods were replicated in the SEER with additional assessment of DSS. Results: A total of 1,778 patients were identified in the FCDS and 6,027 in the SEER. Median diagnosis age was 17 years in both cohorts. In the FCDS, Blacks had worse OS than Whites and Hispanics at 25 years (33% vs. 49.2% vs. 44.7%, respectively; P = 0.0005), and Black race was associated with inferior OS on multivariate regression (hazard ratio [HR]: 1.81, P = 0.0003). In the SEER, Blacks had inferior OS (Blacks 74.2% vs. Whites 82% vs. Hispanics 82%; P = 0.0005) and DSS (85.7% vs. 90.8% vs. 88.1%, respectively; P = 0.0002) at 25 years. Hispanic males had inferior DSS compared to White males (84.8% vs. 90.6%; P = 0.0478), and Hispanic race was a predictor for inferior DSS on multivariate analysis (HR: 1.238; P <0.0001). Conclusions: Racial/ethnic disparities persist in the pediatric HL population despite modern treatment; underlying causes of these disparities are complex and need further examination.

Original languageEnglish (US)
Pages (from-to)428-435
Number of pages8
JournalPediatric Blood and Cancer
Volume63
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hodgkin Disease
Pediatrics
Survival
Population
Hispanic Americans
Epidemiology
Information Systems
Neoplasms
Therapeutics
Multivariate Analysis
Demography

Keywords

  • Epidemiology
  • Hodgkin's lymphoma
  • Long-term survival
  • Lymphoma
  • Pediatric oncology
  • SEER

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Grubb, W. R., Neboori, H. J., Diaz, A. D., Li, H., Kwon, D., & Panoff, J. (2016). Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population. Pediatric Blood and Cancer, 63(3), 428-435. https://doi.org/10.1002/pbc.25802

Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population. / Grubb, W. R.; Neboori, H. J.; Diaz, A. D.; Li, H.; Kwon, D.; Panoff, Joseph.

In: Pediatric Blood and Cancer, Vol. 63, No. 3, 01.03.2016, p. 428-435.

Research output: Contribution to journalArticle

Grubb, WR, Neboori, HJ, Diaz, AD, Li, H, Kwon, D & Panoff, J 2016, 'Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population', Pediatric Blood and Cancer, vol. 63, no. 3, pp. 428-435. https://doi.org/10.1002/pbc.25802
Grubb, W. R. ; Neboori, H. J. ; Diaz, A. D. ; Li, H. ; Kwon, D. ; Panoff, Joseph. / Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population. In: Pediatric Blood and Cancer. 2016 ; Vol. 63, No. 3. pp. 428-435.
@article{e658d2d4d06d4c668c7b0ff2d84581e8,
title = "Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population",
abstract = "Background: Little is known about the association between race/ethnicity and survival in pediatric Hodgkin lymphoma (HL) patients. In a state-wide pediatric cohort diagnosed with HL, we assessed demographic, disease, and treatment characteristics associated with overall survival (OS). We then attempted to validate these findings and assess disease-specific survival (DSS) in a national Surveillance, Epidemiology, and End Results (SEER) cohort. Procedure: HL patients of 0.1-21 years diagnosed from 1981 to 2010 were evaluated using the Florida Cancer Data System (FCDS). Kaplan-Meier curves estimated OS from 5 to 25 years based on race/ethnicity, treatment, decade of diagnosis, and sex. Multivariate Cox proportional hazard regressions tested independent factors associated with differences in OS. These methods were replicated in the SEER with additional assessment of DSS. Results: A total of 1,778 patients were identified in the FCDS and 6,027 in the SEER. Median diagnosis age was 17 years in both cohorts. In the FCDS, Blacks had worse OS than Whites and Hispanics at 25 years (33{\%} vs. 49.2{\%} vs. 44.7{\%}, respectively; P = 0.0005), and Black race was associated with inferior OS on multivariate regression (hazard ratio [HR]: 1.81, P = 0.0003). In the SEER, Blacks had inferior OS (Blacks 74.2{\%} vs. Whites 82{\%} vs. Hispanics 82{\%}; P = 0.0005) and DSS (85.7{\%} vs. 90.8{\%} vs. 88.1{\%}, respectively; P = 0.0002) at 25 years. Hispanic males had inferior DSS compared to White males (84.8{\%} vs. 90.6{\%}; P = 0.0478), and Hispanic race was a predictor for inferior DSS on multivariate analysis (HR: 1.238; P <0.0001). Conclusions: Racial/ethnic disparities persist in the pediatric HL population despite modern treatment; underlying causes of these disparities are complex and need further examination.",
keywords = "Epidemiology, Hodgkin's lymphoma, Long-term survival, Lymphoma, Pediatric oncology, SEER",
author = "Grubb, {W. R.} and Neboori, {H. J.} and Diaz, {A. D.} and H. Li and D. Kwon and Joseph Panoff",
year = "2016",
month = "3",
day = "1",
doi = "10.1002/pbc.25802",
language = "English (US)",
volume = "63",
pages = "428--435",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Racial and Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population

AU - Grubb, W. R.

AU - Neboori, H. J.

AU - Diaz, A. D.

AU - Li, H.

AU - Kwon, D.

AU - Panoff, Joseph

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: Little is known about the association between race/ethnicity and survival in pediatric Hodgkin lymphoma (HL) patients. In a state-wide pediatric cohort diagnosed with HL, we assessed demographic, disease, and treatment characteristics associated with overall survival (OS). We then attempted to validate these findings and assess disease-specific survival (DSS) in a national Surveillance, Epidemiology, and End Results (SEER) cohort. Procedure: HL patients of 0.1-21 years diagnosed from 1981 to 2010 were evaluated using the Florida Cancer Data System (FCDS). Kaplan-Meier curves estimated OS from 5 to 25 years based on race/ethnicity, treatment, decade of diagnosis, and sex. Multivariate Cox proportional hazard regressions tested independent factors associated with differences in OS. These methods were replicated in the SEER with additional assessment of DSS. Results: A total of 1,778 patients were identified in the FCDS and 6,027 in the SEER. Median diagnosis age was 17 years in both cohorts. In the FCDS, Blacks had worse OS than Whites and Hispanics at 25 years (33% vs. 49.2% vs. 44.7%, respectively; P = 0.0005), and Black race was associated with inferior OS on multivariate regression (hazard ratio [HR]: 1.81, P = 0.0003). In the SEER, Blacks had inferior OS (Blacks 74.2% vs. Whites 82% vs. Hispanics 82%; P = 0.0005) and DSS (85.7% vs. 90.8% vs. 88.1%, respectively; P = 0.0002) at 25 years. Hispanic males had inferior DSS compared to White males (84.8% vs. 90.6%; P = 0.0478), and Hispanic race was a predictor for inferior DSS on multivariate analysis (HR: 1.238; P <0.0001). Conclusions: Racial/ethnic disparities persist in the pediatric HL population despite modern treatment; underlying causes of these disparities are complex and need further examination.

AB - Background: Little is known about the association between race/ethnicity and survival in pediatric Hodgkin lymphoma (HL) patients. In a state-wide pediatric cohort diagnosed with HL, we assessed demographic, disease, and treatment characteristics associated with overall survival (OS). We then attempted to validate these findings and assess disease-specific survival (DSS) in a national Surveillance, Epidemiology, and End Results (SEER) cohort. Procedure: HL patients of 0.1-21 years diagnosed from 1981 to 2010 were evaluated using the Florida Cancer Data System (FCDS). Kaplan-Meier curves estimated OS from 5 to 25 years based on race/ethnicity, treatment, decade of diagnosis, and sex. Multivariate Cox proportional hazard regressions tested independent factors associated with differences in OS. These methods were replicated in the SEER with additional assessment of DSS. Results: A total of 1,778 patients were identified in the FCDS and 6,027 in the SEER. Median diagnosis age was 17 years in both cohorts. In the FCDS, Blacks had worse OS than Whites and Hispanics at 25 years (33% vs. 49.2% vs. 44.7%, respectively; P = 0.0005), and Black race was associated with inferior OS on multivariate regression (hazard ratio [HR]: 1.81, P = 0.0003). In the SEER, Blacks had inferior OS (Blacks 74.2% vs. Whites 82% vs. Hispanics 82%; P = 0.0005) and DSS (85.7% vs. 90.8% vs. 88.1%, respectively; P = 0.0002) at 25 years. Hispanic males had inferior DSS compared to White males (84.8% vs. 90.6%; P = 0.0478), and Hispanic race was a predictor for inferior DSS on multivariate analysis (HR: 1.238; P <0.0001). Conclusions: Racial/ethnic disparities persist in the pediatric HL population despite modern treatment; underlying causes of these disparities are complex and need further examination.

KW - Epidemiology

KW - Hodgkin's lymphoma

KW - Long-term survival

KW - Lymphoma

KW - Pediatric oncology

KW - SEER

UR - http://www.scopus.com/inward/record.url?scp=84956795726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956795726&partnerID=8YFLogxK

U2 - 10.1002/pbc.25802

DO - 10.1002/pbc.25802

M3 - Article

C2 - 26524117

AN - SCOPUS:84956795726

VL - 63

SP - 428

EP - 435

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -